Trial Profile
Randomized, phase III, comparative study of every-3-weeks dosing, weekly dosing of ABI-007, and weekly dosing of the conventional paclitaxel for patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms ABSOLUTE
- Sponsors Taiho Pharmaceutical
- 06 Jun 2017 Primary endpoint (Overall Survival:OS (q1w nab-PTX (100 mg/m2) vs q1w sb-PTX (80 mg/m2))) has not been met as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Primary endpoint (Overall Survival:OS (q3w nab-PTX (260 mg/m2) vs q1w sb-PTX (80 mg/m2))) has been met as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology